MAIA Biotechnology
MAIA
26 hedge funds and large institutions have $4.09M invested in MAIA Biotechnology in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 0 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
37% more funds holding
Funds holding: 19 → 26 (+7)
17% more capital invested
Capital invested by funds: $3.49M → $4.09M (+$604K)
0.4% less ownership
Funds ownership: 7.19% → 6.8% (-0.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$103K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$67.5K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
+$37.6K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$33.5K |
| 5 |
RWM
Ritholtz Wealth Management
New York
|
+$30.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$170K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| $46 | +$1 | +1 | +3% |
|
|
27
Marshall Wace
London,
United Kingdom
| – | -$170K | -110,467 | Closed |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| – | -$6.2K | -4,026 | Closed |
|
MAIA Hedge Fund Activity: Q4 2025 in Review
26 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in MAIA Biotechnology (MAIA) for Q4 2025, worth a combined $4.09M — up 17% from $3.49M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new MAIA positions and 2 closed out — a net gain of 7 holders — while 8 added to existing stakes and 0 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $103K. The largest seller was Marshall Wace, exiting entirely with an estimated $170K sold.
- 26 institutional investors held MAIA Biotechnology (MAIA) as of Q4 2025, up from 19 in Q3 2025.
- Funds reported $4.09M of MAIA Biotechnology stock for Q4 2025, up 17% quarter-over-quarter.
- 9 funds opened new MAIA Biotechnology positions in Q4 2025 and 2 closed out, a net change of +7 holders.
- The largest MAIA Biotechnology buyer in Q4 2025 was Jane Street, an estimated $103K added.
- The largest MAIA Biotechnology seller in Q4 2025 was Marshall Wace, an estimated $170K sold.
Based on aggregated 13F filings for Q4 2025.